Clinical Trial

Efficiency of Vaccination with Lysate-loaded Dendritic Cells in Patients with Newly Diagnosed Glioblastoma

Study acronym: GlioVax
Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The primary objective of the study is to determine whether overall survival of newly diagnosed glioblastoma patients treated with lysate-loaded, mature dendritic cell vaccines as add-on to the standard of care consisting of resection, radiotherapy with concomitant temozolomide chemotherapy and subsequent adjuvant temozolomide chemotherapy is superior to the treatment with the standard of care alone.
Protocol Amendment History 7 amendments
This ClinicalTrials.gov record has been amended 7 times since 2018-01-09; most recent amendment 2024-11-27.
Status change: Recruiting → Active, Not Recruiting 2024-11-27
Status change: Not Yet Recruiting → Recruiting 2018-05-08
Trial Details
NCT Number NCT03395587
Lead Sponsor Heinrich-Heine University, Duesseldorf
Collaborators: German Federal Ministry of Education and Research
Conditions Glioblastoma
Enrollment 136 participants
Start Date 2018-03-06
Primary Completion 2027-05 (estimated)
Study Completion 2027-05 (estimated)
Updated on ClinicalTrials.gov 2024-12-02